Cargando…

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ríos-Tamayo, Rafael, Martín-García, Agustín, Alarcón-Payer, Carolina, Sánchez-Rodríguez, Dolores, de la Guardia, Ana María del Valle Díaz, García Collado, Carlos Gustavo, Jiménez Morales, Alberto, Jurado Chacón, Manuel, Cabeza Barrera, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574598/ https://www.ncbi.nlm.nih.gov/pubmed/28860711 http://dx.doi.org/10.2147/DDDT.S115456

Ejemplares similares

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Young, Mary H., et al.
Publicado: (2021)

Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
por: Zhuang, Yan, et al.
Publicado: (2023)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
por: Lopez-Millan, Belen, et al.
Publicado: (2017)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014)

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
por: Matsue, Kosei, et al.
Publicado: (2015)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis
por: Chen, Runzhe, et al.
Publicado: (2017)

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM
por: Sunami, Kazutaka, et al.
Publicado: (2020)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
por: Paíno, Teresa, et al.
Publicado: (2020)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
por: Zhang, Qiqi, et al.
Publicado: (2022)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
por: Yuping, Z., et al.
Publicado: (2022)

Cryptococcosis in a patient with multiple myeloma receiving pomalidomide: a case report and literature review
por: Chastain, Daniel B., et al.
Publicado: (2022)

Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
por: Lovas, Szilvia, et al.
Publicado: (2022)

Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients
por: Wang, Xi, et al.
Publicado: (2022)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Publicado: (2023)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
por: Li, Yan, et al.
Publicado: (2017)

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
por: Krishnan, Amrita, et al.
Publicado: (2018)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8he4ngge938sat93lb98tl0jn3